Rocket Pharmaceuticals, Inc. Warrant
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; l… Read more
Rocket Pharmaceuticals, Inc. Warrant (RCKTW) - Total Liabilities
Latest total liabilities as of September 2024: $63.92 Million USD
Based on the latest financial reports, Rocket Pharmaceuticals, Inc. Warrant (RCKTW) has total liabilities worth $63.92 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Rocket Pharmaceuticals, Inc. Warrant - Total Liabilities Trend (2019–2023)
This chart illustrates how Rocket Pharmaceuticals, Inc. Warrant's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Rocket Pharmaceuticals, Inc. Warrant Competitors by Total Liabilities
The table below lists competitors of Rocket Pharmaceuticals, Inc. Warrant ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GLG LIFE TECH (9LTN.SG)
STU:9LTN
|
Germany | €193.48 Million |
|
MEGASTAR DEV
BE:M5QN
|
Germany | €241.56K |
|
FIRST SHANGHAI INV
BE:FSI
|
Germany | €3.19 Billion |
|
Haus Talk Inc
PSE:HTI
|
Philippines | ₱1.18 Billion |
Liability Composition Analysis (2019–2023)
This chart breaks down Rocket Pharmaceuticals, Inc. Warrant's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rocket Pharmaceuticals, Inc. Warrant's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rocket Pharmaceuticals, Inc. Warrant (2019–2023)
The table below shows the annual total liabilities of Rocket Pharmaceuticals, Inc. Warrant from 2019 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $73.77 Million | +18.75% |
| 2022-12-31 | $62.12 Million | +46.87% |
| 2021-12-31 | $42.30 Million | -51.55% |
| 2020-12-31 | $87.31 Million | +34.68% |
| 2019-12-31 | $64.82 Million | -- |